1. Home
  2. Present
  3. Case Submission Guidelines
CASE SUBMISSION GUIDELINES

The workshop panel will collate and discuss all cases submitted to the Workshop. All cases will be organized into eight sessions using the topics chosen by the submitter in the online system but may be rescheduled at the discretion of the Workshop Panel. Approximately 40 cases (4 or 5 cases per session) will be presented during the meeting. Early submissions are strongly encouraged.

Alert!  Case Submission will open in Fall 2026

Case Topics

  • The focus of the 2027 Workshop is hematolymphoid disorders arising in the setting of immune dysregulation.

    • Lymph node, extranodal, and bone marrow pathology in primary immune deficiency (PID)
      • Examples of various PIDs such as (but not limited to) chronic variable immunodeficiency (CVID), hyper IgM syndrome, PI3K-related immunodeficiencies, Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) deficiency, autoimmune lymphoproliferative syndrome (ALPS), WHIM syndrome, etc.
    • Post-transplant lymphoproliferative disorder (PTLD; excluding monomorphic PTLD unless listed below)
      • Non-destructive PTLD – i.e. infectious mononucleosis-like, follicular hyperplasia and plasmacytic hyperplasia
      • Marginal zone lymphoma, Epstein-Barr virus positive and negative in the post transplantation setting
      • PTLD cases which highlight the difficulties in differentiating between polymorphic and monomorphic PTLD
      • T- and NK-cell PTLDs
    • Iatrogenic immunodeficiency-associated hematolymphoid disorders
      • Examples of myeloid and lymphoid proliferations and neoplasms in patients on various immunosuppressive/ immunomodulatory agents, including newer agents (such as monoclonal antibodies, gene therapy, and CAR T-cell therapy), for example CAR T-derived lymphoproliferative disorders
      • Lenalidomide-associated myeloid and/or lymphoid neoplasms
    • Epstein-Barr virus (EBV)-associated lymphoproliferative disorders (LPD)
      • Cases with overlapping features between EBV-positive classic Hodgkin lymphoma, EBV positive NLP, and EBV-positive diffuse large B-cell lymphoma
      • Lymphomatoid granulomatosis
      • EBV-positive polymorphic B-cell LPD, NOS (both, nodal and extranodal) and mucocutaneous ulcer (in particular cases that overlap with polymorphic B-LPD)
      • EBV-positive plasma cell neoplasms (excluding classic cases of plasmablastic lymphoma) – i.e. EBV-positive plasmacytoma (including cases with plasmablastic morphology that overlap with plasmablastic lymphoma) and plasma cell myeloma
    • Somatic mutations associated with immune dysregulation and neoplasia
      • VEXAS
      • RAS-associated autoimmune leukoproliferative disorder (RALD)
      • Examples of cases with somatic mutations associated with hemophagocytic lymphohistiocytosis (HLH), such as FAS mutations
      • Examples of lymphoid neoplasms arising in setting of clonal hematopoiesis of indeterminate potential (CHIP), excluding T-follicular helper lymphomas
    • Bone marrow pathology associated with immune dysregulation
      • Myeloid neoplasia and mimics arising in the setting of immune-acting drugs other than alkylating or topoisomerase-inhibitor chemotherapy, such as azathioprine, antithymocyte globulin, methotrexate
      • Autoimmune myelofibrosis and other bone marrow changes associated with autoimmunity
      • HIV-associated myeloid disorders and alterations to the bone marrow microenvironment

Case Submission Information

Please note the following guidelines for case submission. The online submission system will automatically enforce these guidelines:

  • Case text is limited to 3,500 characters
  • Please structure your case as follows:
    • Clinical Information
    • Description of Submitted Tissues, including fixative and decalcification method (if applicable)
    • Details of Microscopic Findings
    • Immunophenotype
    • Cytogenetics
    • Molecular Studies
    • Proposed Diagnosis/ses
    • Interesting Features of Case
  • Molecular characterization will be performed as needed on select cases.
  • Tissue Submission: Each case should include the submission of (1) one H&E slide of representative tissue per specimen and, if available, 10 unstained slides. The submitted H&E slide will also be made available to all workshop attendees in the form of digital whole slide imaging.
    • Each case should include the submission of (1) one H&E slide of representative tissue per specimen. Submitters may be contacted directly, as needed, to submit additional unstained slides for immunohistochemical studies. The submitted H&E slide may also be made available to all workshop attendees in the form of digital whole slide imaging, if your case is selected for individual presentation.

      • Address for Slide Submission:
      Children's Hospital of Philadelphia
      C/O Rachel Olson
      3401 Civic Center Blvd.
      Main Hospital, 5th Floor, Room 5NW81
      Philadelphia, PA 19104

  • Please upload your slides (max. 10 MB, PowerPoint) using the provided template.
  • All cases must contain original work and content that has not been published in a peer-review journal.
  • The case submission fee is 35 USD.
  • Cases must be submitted in English. Please check spelling and grammar carefully.